Clinical trial
BCG Plus Interferon Alfa 2b in Treating Patients With Bladder Cancer
NCT00004122 · Roswell Park Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00004122 |
|---|---|
| Title | BCG Plus Interferon Alfa 2b in Treating Patients With Bladder Cancer |
| Official title | A National Phase II Trial of Intron (Interferon-alfa 2b) Plus BCG for Treatment of Superficial Bladder Cancer |
| Lead sponsor | Roswell Park Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Bladder Cancer |
| Intervention type | Biological |
| Interventions | BCG vaccine, recombinant interferon alfa |
| Start date | Jul 1, 1999 |
| Primary completion | Apr 1, 2001 |
| First posted | May 21, 2004 |
| Last update posted | Feb 1, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: